(Incorporated in Delaware) 

We are a Phase 1 clinical biopharmaceutical company developing next-generation biologics for immune-mediated diseases. We use our ATTOBODY platform, a biparatropic nanobody-based technology licensed from Alamar Biosciences. We have no products on the market. And we have no revenue from product sales. 

Our lead drug candidate, ATTO-1310, is an ATTOBODY-based therapeutic that targets IL-31 (interleukin-31). We completed dosing in a Phase 1 clinical trial in healthy volunteers and patients with chronic pruritus and atopic dermatitis in the first quarter of 2026.

Our second candidate, ATTO-2306, is an ATTOBODY-based bispecific targeting IL-13 and IL-31 for atopic dermatitis and related skin conditions. It’s in IND-enabling studies with a Phase 1 trial planned for the first half of 2027. (IND stands for investigational new drug.)

Our third candidate, ATTO-1091, is a trispecific ATTOBODY-based Fc fusion protein designed to block TL1A, IL-23, and integrin a4ß7 simultaneously for inflammatory bowel disease; this drug candidate is also in IND-enabling studies. 

Note: Collaboration revenue is for the 12 months that ended on March 31, 2026.

(Note: Attovia Therapeutics priced its IPO in sync with its upsized terms – 17 million shares at $17.00 each – to raise $289 million on Tuesday night, Aug. 4, 2026. Background: Attovia Therapeutics upsized its IPO on Aug. 4, 2026, to 17 million shares – up from 12.5 million shares originally – and set the IPO price at $17.00 – the top of its previous range of $15.00 to $17.00 – to raise $289 million, according to its S-1/A filing on Aug. 4, 2026. Background: Attovia Therapeutics disclosed the terms for its IPO on July 29, 2026, in an S-1/A filing: 12.5 million shares at a price range of $15.00 to $17.00 to raise $200 million, if priced at the $16.00 mid-point of its range. Background: Attovia Therapeutics filed its S-1 for its IPO on July 14, 2026, without disclosing the terms. Estimated proceeds were $100 million, a placeholder figure.)